Recent Company News

• 05:21 PM ET Dec 09, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 07:49 AM ET Dec 09, 2025
  

  Johnson & Johnson announces new data from the investigational Phase 3 MajesTEC-3 study ($201.62, 0.00)

• 04:49 PM ET Dec 08, 2025
  

  Genmab reports data from Phase 1b/2 EPCORE CLL-1 trial evaluating epcoritamab-bysp as monotherapy and in combination for treatment of RT (DKK 2056.00, 0.00)

• 08:04 PM ET Dec 07, 2025
  

  Johnson & Johnson presents final OS results from Asia patients of MARIPOSA study of RYBREVANT plus LAZCLUZE ($201.93, 0.00)

• 10:14 AM ET Dec 07, 2025
  

  Genmab presents, publishes data from EPCORE FL-1 study of EPKINLY (DKK 2032.00, 0.00)

• 12:35 PM ET Dec 06, 2025
  

  Genmab announces data from multiple clinical trials showing treatment with fixed-duration Epcoritamab led to remissions in first-line DLBCL and FL (DKK 2032.00, 0.00)

• 10:16 PM ET Dec 05, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:41 PM ET Dec 05, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 07-Dec

• 10:39 AM ET Dec 04, 2025
  

  Transcript Intelligence: Genmab at Citi Global Healthcare Conference (DKK2059.00, +36.00)

• 02:20 AM ET Dec 03, 2025
  

  NICE recommends Johnson & Johnson's Talvey to treat relapsed and refractory multiple myeloma after 3 or more treatments ($205.42, 0.00)